available for iOS, Android & web
May 24, 2012
In final guidance, NICE has recommended the use of Bayer HealthCare's Xarelto (rivaroxaban) as an option for the prevention of stroke and systemic embolism in people with atrial fibrillation (AF).
April 03, 2012
Following the receipt of further evidence from Bayer HealthCare of Xarelto's clinical and cost-effectiveness, NICE has issued final draft guidance recommending it an option for the prevention of stroke and systemic embolism in people with atrial fibrillation.
March 29, 2012
Boehringer Ingelheim has announced that it is reducing the cost of its oral anticoagulant Pradaxa (dabigatran etexilate) by 13%, to £2.20 per day, from April 1.
January 10, 2012
NICE has published preliminary recommendations asking Bayer for more information on its oral anticoagulant Xarelto (rivaroxaban).
December 20, 2011
Following new European Commission approvals, Bayer's Xarelto is now available for use in the UK for two new indications.
Recruitment agencies provide the unique bridge to [more]...
International Clinical Researcher of the Year 2016
Book your tickets today!
PharmaTimes 2015 Copyright | RSS Feed Subscriptions